EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition

Yongjian Tang, Lisa Sprinzen, Yukinori Terada, Karrie M Kiang, Chuntao Li, Yu Zeng, Fangkun Liu iD, Hongshu Zhou, Xisong Liang, Jianzhong Zhang, Russell O Pieper, Bo Chen iD und 1 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Yongjian Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery and the UCSF Brain Tumor Center, The University of California-San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Hydrazines, Autophagy, Triazoles, Karyopherins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Health Technology Project, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Selinexor is a selective inhibitor of exportin-1 (XPO1), a key mediator of the nucleocytoplasmic transport for molecules critical to tumor cell survival. Selinexor’s lethality is generally associated with the induction of apoptosis, and in some cases, with autophagy-induced apoptosis. We performed this study to determine Selinexor’s action in glioblastoma (GBM) cells, which are notoriously resistant to apoptosis.

Methods

Patient-derived GBM cells were treated with Selinexor, and drug response and autophagy levels were monitored. Homozygous C528S XPO1 mutant GBM43 cells were generated by CRISPR/Cas9 editing. Single Selinexor or combination treatment with autophagy inhibitors was evaluated. In addition, bulk-tissue, single-cell, and spatial transcriptome were analyzed, and molecular docking was performed.

Results

Although all cell lines exhibited a dose- and time-dependent reduction of cell viability, the most profound molecular response to Selinexor was induction of autophagy instead of apoptosis. Selinexor-induced autophagy was an on-target consequence of XPO1 inhibition, and could be mitigated by expression of a mutant, Selinexor-resistant form of XPO1, and Selinexor-induced autophagy was related at least in part to nuclear trapping of the transcription factor TFEB. Furthermore, genetic or pharmacologic suppression of autophagy sensitized the cells to Selinexor-induced toxicity in association with the induction of apoptosis. Finally, in intracranial PDX studies, the combination of Selinexor with the autophagy inhibitor chloroquine significantly impeded tumor growth and extended mouse survival relative to single-agent treatment.

Conclusion

These results suggest that activation of autophagy confers a protective mechanism against Selinexor in GBM cells, and that the combination of Selinexor with autophagy inhibitors may serve as a viable means to enhance Selinexor-induced cell death.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrazinesAutophagyTriazolesKaryopherinsReceptors, Cytoplasmic and NuclearGlioblastomaBrain NeoplasmsHumansExportin 1 ProteinAnimalsMiceApoptosisXenograft Model Antitumor AssaysTumor Cells, CulturedCell ProliferationCell SurvivalCell Line, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

SelinexorXPO1autophagygliomanuclear export

Substanzen

selinexorHydrazinesExportin 1 ProteinTriazolesKaryopherinsReceptors, Cytoplasmic and Nuclear

Autor:innen und Institutionen

  • Department of Neurological Surgery and the UCSF Brain Tumor Center, The University of California-San Francisco, San Francisco, California, USA.
  • Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Hypothalamic Pituitary Research Centre, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Neurosurgery, Xiangya Hospital, Central South University, Jiangxi. (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, China.
  • Jiangxi Provincial People's Hospital, Clinical College of Nanchang Medical College, First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.

ORCID-Profile: Fangkun Liu, Bo Chen, Liyang Zhang

Förderung

  • National Natural Science Foundation of China
  • Jiangxi Provincial Health Technology Project
  • NCI NIH HHS
  • Natural Science Foundation of Hunan Province
  • Jiangxi Provincial Natural Science Foundation

Zitieren

APA

Tang, Y., Sprinzen, L., Terada, Y., Kiang, K. M., Li, C., Zeng, Y., Liu, F., Zhou, H., Liang, X., Zhang, J., Pieper, R. O., Chen, B., & Zhang, L. (2025). Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae280

Vancouver

Tang Y, Sprinzen L, Terada Y, Kiang KM, Li C, Zeng Y, et al. Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae280

BibTeX
@article{Tang2025,
  author = {Tang, Yongjian and Sprinzen, Lisa and Terada, Yukinori and Kiang, Karrie M and Li, Chuntao and Zeng, Yu and Liu, Fangkun and Zhou, Hongshu and Liang, Xisong and Zhang, Jianzhong and Pieper, Russell O and Chen, Bo and Zhang, Liyang},
  title = {Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae280}
}
Kostenlos starten →